A Phase Ib/II Study of Pembrolizumab and Monoclonal Antibody Therapy in Patients With Advanced Cancer (PembroMab

Trial Profile

A Phase Ib/II Study of Pembrolizumab and Monoclonal Antibody Therapy in Patients With Advanced Cancer (PembroMab

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Nov 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Cetuximab; Trastuzumab; Trastuzumab emtansine
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Nov 2017 Planned End Date changed from 1 Oct 2017 to 1 Dec 2018.
    • 24 Nov 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Jun 2018.
    • 23 Jun 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top